A patient received the first dose of the two‑dose human papillomavirus (HPV) vaccine ten years ago; should they now receive the second dose?

Should a Patient Complete HPV Vaccination After a 10-Year Delay?

Yes, the patient should receive the remaining dose(s) to complete the HPV vaccine series, as interrupted schedules do not require restarting and protection against HPV-related cancers and precancers remains highly beneficial regardless of the delay. 1

Key Principle: No Need to Restart the Series

• The HPV vaccine series does not need to be restarted regardless of how long the interruption has been. 1
• If the series is interrupted after the first dose, the second dose should be administered as soon as possible. 1
• There is no maximum interval beyond which previous doses become invalid—even a 10-year gap does not negate the first dose. 1

Determining How Many Additional Doses Are Needed

The number of remaining doses depends on the patient's age when they received the first dose 10 years ago:

If First Dose Was Given Before Age 15:

• Only ONE additional dose is needed to complete the series (total of 2 doses). 1, 2
• The 2-dose schedule applies to anyone who initiates the series before their 15th birthday, regardless of when subsequent doses are given. 1, 2
• For example, if the patient received dose 1 at age 14 (now age 24), they need only one more dose—not two. 1, 2

If First Dose Was Given at Age 15 or Older:

• TWO additional doses are needed to complete the 3-dose series. 1, 2
• The 3-dose schedule (0,1-2 months, 6 months from dose 2) applies when vaccination is initiated at age 15 or older. 1, 2

Immunologic Rationale for Completion

• Robust immune memory persists years after a single dose, with studies showing 95-98% seropositivity for HPV16/18 even 3-10 years after one dose. 3, 4
• A delayed second dose administered years later produces a strong anamnestic (booster) response, with 60-91-fold increases in antibody titers and 100% seroconversion. 3, 4
• Memory B cells remain detectable and functional, ensuring that completion of the series—even after prolonged delay—generates protective immunity comparable to on-schedule vaccination. 5

Clinical Benefit Regardless of Sexual Activity

• Even if the patient has been sexually active during the 10-year interval, vaccination still provides substantial benefit. 1
• Most sexually active individuals are unlikely to have been infected with all HPV vaccine types, so completion protects against types not yet acquired. 1
• HPV infection risk continues as long as individuals remain sexually active, making catch-up vaccination valuable at any point. 1
• No HPV testing or Pap screening is required before completing the series—vaccination is recommended regardless of prior HPV exposure or abnormal cytology. 1

Age Considerations for Catch-Up Vaccination

• Routine catch-up vaccination is recommended through age 26 for all persons who have not completed the series. 1, 2
• For adults aged 27-45 years, the ACIP recommends shared clinical decision-making based on individual risk assessment, recognizing that some may still benefit from vaccination. 1
• If the patient is now ≤26 years old, completion is unequivocally recommended. 1, 2
• If the patient is 27-45 years old, discuss their ongoing risk for new HPV exposure and potential benefit from series completion. 1

Practical Implementation

• Administer the next dose as soon as possible without waiting for any specific interval from the 10-year mark. 1
• Use the 9-valent HPV vaccine (9vHPV), which is the only HPV vaccine currently available in the United States as of 2017 and provides broader protection than earlier formulations. 1
• The vaccine can be given at the same visit as other indicated vaccines. 1, 2
• If a 3-dose series is needed (first dose at age ≥15), the minimum interval between doses 2 and 3 is 12 weeks, though the standard 6-month interval is preferred. 1

Common Pitfalls to Avoid

• Do not restart the series from scratch—this wastes the immunity already established by the first dose. 1
• Do not assume the patient needs 3 doses without confirming their age at first vaccination—those who started before age 15 need only 2 total doses. 1, 2
• Do not delay completion while waiting for HPV testing or cervical screening results—these are not prerequisites for vaccination. 1
• Do not withhold vaccination based on assumptions about prior HPV exposure—partial protection is still highly valuable. 1

Impact on Cancer Prevention

• HPV vaccination prevents approximately 70-90% of HPV-related cancers, including cervical, oropharyngeal, anal, vaginal, vulvar, and penile cancers. 1
• Real-world effectiveness data demonstrate that even a single dose provides 80-83% protection against HPV16/18 infection over 11 years, with completion likely enhancing durability. 6, 7
• Completing the series maximizes long-term protection against these potentially fatal malignancies. 6, 7, 8